Tocotrienol Against the Progression of End Stage Liver Disease
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase 2 trial is to validate the outcome observed in a previous trial
that oral Tocotrienol (TCT) attenuates the rise in MELD score over time in patients with end
stage liver disease / cirrhosis. The study is double blind and participants will be
randomized to take 2 capsules of TCT (200mg) or placebo twice a day for 3 years.